Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.
'We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,' said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. 'This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.'
The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day.
'In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,' said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. 'The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.'
For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit thermofisher.com/oncomine-ocaplus.
*For Research Use Only. Not for use in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
LifeX Term Income ETFs Announce the Closure and Liquidation of Two Exchange-Traded Funds
NEW YORK--(BUSINESS WIRE)--LifeX Term Income ETFs ('LifeX') has announced that it will close and liquidate two exchange-traded funds to simplify its fund lineup. LifeX will be liquidating the LifeX 2040 Term Income ETF and LifeX 2045 Term Income ETF (together, the 'Liquidating ETFs') (such transactions, the 'Liquidations'). The Liquidations are expected to take place on or about August 22, 2025 (the 'Liquidation Date'). August 20, 2025 is expected to be the last full day of trading for the Liquidating ETFs' shares. The Liquidating ETFs expect to operate pursuant to their stated investment strategies through the Liquidation Date. While the investment objective of each Liquidating ETF is to provide monthly distributions through the year in such Liquidating ETF's name, the Liquidating ETFs will instead seek to liquidate and distribute their remaining assets to shareholders promptly following the Liquidation Date. In each case, the liquidation proceeds are expected to be distributed promptly following the Liquidation Date in full redemption of each shareholder's shares of the Liquidating ETFs. For additional information about the liquidations, shareholders of the Liquidating ETFs may call 855-609-3680. About LifeX Term Income ETFs LifeX Term Income ETFs are designed to provide reliable monthly distributions consisting of income and principal through the end of a calendar year specified in the ETF's prospectus. To learn more, please visit Risk Disclosures Investing involves risk. Principal loss is possible. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus with this and other information about the fund, please visit or call 855-609-3680. Please read the prospectus carefully before investing. Distributed by Foreside Financial Services, LLC.
Associated Press
25 minutes ago
- Associated Press
LifeX Term Income ETFs Announce the Closure and Liquidation of Two Exchange-Traded Funds
NEW YORK--(BUSINESS WIRE)--Aug 15, 2025-- LifeX Term Income ETFs ('LifeX') has announced that it will close and liquidate two exchange-traded funds to simplify its fund lineup. LifeX will be liquidating the LifeX 2040 Term Income ETF and LifeX 2045 Term Income ETF (together, the 'Liquidating ETFs') (such transactions, the 'Liquidations'). The Liquidations are expected to take place on or about August 22, 2025 (the 'Liquidation Date'). August 20, 2025 is expected to be the last full day of trading for the Liquidating ETFs' shares. The Liquidating ETFs expect to operate pursuant to their stated investment strategies through the Liquidation Date. While the investment objective of each Liquidating ETF is to provide monthly distributions through the year in such Liquidating ETF's name, the Liquidating ETFs will instead seek to liquidate and distribute their remaining assets to shareholders promptly following the Liquidation Date. In each case, the liquidation proceeds are expected to be distributed promptly following the Liquidation Date in full redemption of each shareholder's shares of the Liquidating ETFs. For additional information about the liquidations, shareholders of the Liquidating ETFs may call 855-609-3680. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus with this and other information about the fund, please visit or call 855-609-3680. Please read the prospectus carefully before investing. Distributed by Foreside Financial Services, LLC. View source version on CONTACT: Media Contact Marc Feuerstein [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: ASSET MANAGEMENT PROFESSIONAL SERVICES FINANCE SOURCE: Stone Ridge Holdings Group Copyright Business Wire 2025. PUB: 08/15/2025 05:00 PM/DISC: 08/15/2025 05:00 PM
Business Wire
an hour ago
- Business Wire
Materion to Participate in the Seaport Research Partners Annual Summer Conference
MAYFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--Materion Corporation (NYSE: MTRN) will participate in the Seaport Research Partners Annual Summer Conference on August 20, 2025. Jugal Vijayvargiya, President and Chief Executive Officer and Shelly Chadwick, Vice President, Finance and Chief Financial Officer, will be available for one-on-one meetings with investors throughout the day. About Materion Materion Corporation is a global leader in advanced materials solutions for high-performance industries including semiconductor, industrial, aerospace & defense, energy and automotive. With nearly 100 years of expertise in specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings, Materion partners with customers to enable breakthrough solutions that move the world forward. Headquartered in Mayfield Heights, Ohio, the company employs more than 3,000 people worldwide, serving customers in more than 60 countries.
